Journal of Psychopharmacology最新文献

{"title":"No differences in neural responses or performance during cannabis cue-specific inhibitory control tasks between recreational cannabis users and non-users: Insights from fNIRS.","authors":"Christopher R Pickering, Valentina Lorenzetti, Andrew Jones, Martin Guest, Paul Christiansen, Carl A Roberts","doi":"10.1177/02698811251358814","DOIUrl":"https://doi.org/10.1177/02698811251358814","url":null,"abstract":"<p><strong>Background: </strong>Impaired inhibitory control has been observed in regular cannabis users. Theories suggest that regular cannabis use is maintained by reward-driven behaviour, which may be underpinned by adaptations in neural reward and inhibitory control systems, thus increasing vulnerability to dependency.</p><p><strong>Aims: </strong>This study investigated neural correlates of cannabis cue-specific inhibitory control in regular cannabis users and non-users using functional near-infrared spectroscopy (fNIRS).</p><p><strong>Methods: </strong>Thirty regular cannabis users and thirty non-user controls completed two inhibitory control tasks (Go/No/Go and Stop-Signal Task), and a measure of attentional bias (Cannabis Stroop task). fNIRS recorded prefrontal and orbitofrontal haemodynamic responses (oxygenated haemoglobin and deoxygenated haemoglobin). Group comparisons and exploratory regressions examined cannabis use characteristics as predictors of behavioural and neural outcomes.</p><p><strong>Results: </strong>No significant group differences were found in behavioural performance or haemodynamic activity across tasks. Exploratory regressions showed no significant associations between cannabis use characteristics and behavioural or neural outcomes after adjusting for covariates.</p><p><strong>Conclusions: </strong>No evidence of impaired inhibitory control, attentional bias, or differences in prefrontal function were found in non-dependent cannabis users. Future studies should investigate whether such deficits emerge with heavier or dependent use.</p>","PeriodicalId":16892,"journal":{"name":"Journal of Psychopharmacology","volume":" ","pages":"2698811251358814"},"PeriodicalIF":5.5,"publicationDate":"2025-10-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145206702","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Disrupted network integrity and therapeutic plasticity in drug-naive panic disorders: Insights from network homogeneity.","authors":"Yiding Han, Haohao Yan, Huabing Li, Feng Liu, Ping Li, Yonggui Yuan, Wenbin Guo","doi":"10.1177/02698811251362352","DOIUrl":"https://doi.org/10.1177/02698811251362352","url":null,"abstract":"<p><strong>Background: </strong>This study intended to examine network homogeneity (NH) alterations in drug-naive patients with panic disorder (PD) before and after treatment and whether NH could serve as a potential biomarker.</p><p><strong>Methods: </strong>Fifty-eight patients and 85 healthy controls (HCs) underwent resting-state functional magnetic resonance imaging. Patients were rescanned following a 4-week course of paroxetine monotherapy. NH was computed to evaluate intra-network functional integration across the Yeo 7-Network. Machine learning (ML) was employed to assess the diagnostic and prognostic potential of NH metrics. Transcriptome-neuroimaging association analyses were conducted to explore the molecular correlates of NH alterations.</p><p><strong>Results: </strong>Compared with HCs, patients showed disrupted intra-network integration in the frontoparietal, default mode, sensorimotor, limbic, and ventral attention networks, with prominent NH alterations in the superior frontal gyrus (SFG), middle temporal gyrus (MTG), superior temporal gyrus (STG), somatosensory cortex, insular, and anterior cingulate cortex. Importantly, the SFG, MTG, and STG demonstrated cross-network abnormalities. After treatment, clinical improvement correlated with normalized NH in the SFG and additional changes in the inferior occipital gyrus and calcarine sulcus within the visual network. ML demonstrated the utility of NH for PD classification and treatment outcome prediction. Transcriptome-neuroimaging analysis identified specific gene profiles related to NH alterations.</p><p><strong>Conclusions: </strong>NH reflects both pathological features and treatment-related changes in PD, providing a measure of network dysfunction and therapeutic response. Cross-network NH disruptions in hub regions and visual processing may reflect core neuropharmacological mechanisms underlying PD. ML findings support the potential of NH as a neuroimaging biomarker for diagnosis and treatment monitoring in PD.</p>","PeriodicalId":16892,"journal":{"name":"Journal of Psychopharmacology","volume":" ","pages":"2698811251362352"},"PeriodicalIF":5.5,"publicationDate":"2025-10-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145206716","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Can cannabinoids alleviate behavioral symptoms in older adults with dementia? A systematic review.","authors":"Adele Ravelli, Chiara Ceolin, Mario Virgilio Papa, Margherita Vergadoro, Maria Devita, Marina De Rui, Paolo Simioni, Giuseppe Sergi, Alessandra Coin","doi":"10.1177/02698811251375895","DOIUrl":"https://doi.org/10.1177/02698811251375895","url":null,"abstract":"<p><strong>Background: </strong>Behavioral and psychological symptoms of dementia (BPSD) affect patients' and caregivers' well-being. Cannabinoids may offer a promising therapeutic option for managing BPSD.</p><p><strong>Aims: </strong>This systematic review aims to explore the strengths of using this class of substances in the context of dementia care.</p><p><strong>Methods: </strong>We conducted a comprehensive search across Embase Ovid, PubMed, Cochrane Library, APA PsycInfo, and Web of Science, identifying 1839 studies, with 14 selected for full review. Quality was assessed using the Newcastle-Ottawa and the modified Jadad Scales.</p><p><strong>Results/outcomes: </strong>Ten studies (278 participants) were finally included. They showed cannabinoids helped reduce agitation and nocturnal disturbances.</p><p><strong>Conclusions/interpretation: </strong>In conclusion, cannabinoids show promise in managing BPSD in dementia, with good tolerability and safety. Further studies could solidify these findings.</p>","PeriodicalId":16892,"journal":{"name":"Journal of Psychopharmacology","volume":" ","pages":"2698811251375895"},"PeriodicalIF":5.5,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145206636","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Incident benzodiazepine and Z-drug use and subsequent risk of alcohol- and drug-related problems: A nationwide matched cohort study with co-twin comparison.","authors":"Xinchen Wang, Zheng Chang, Yasmina Molero, Kayoko Isomura, Lorena Fernández de la Cruz, Paul Lichtenstein, Ralf Kuja-Halkola, Brian M D'Onofrio, Patrick D Quinn, Henrik Larsson, Isabell Brikell, Clara Hellner, Jan Hasselström, Nitya Jayaram-Lindström, David Mataix-Cols, Anna Sidorchuk","doi":"10.1177/02698811251373069","DOIUrl":"https://doi.org/10.1177/02698811251373069","url":null,"abstract":"<p><strong>Background: </strong>Despite considerable interest in the consequences of benzodiazepine and benzodiazepine-related Z-drug (BZDR) use, little is known about whether and how initiation of BZDR treatment relates to the development of alcohol- and drug-related problems.</p><p><strong>Aims: </strong>This study aimed to examine the association of incident BZDR dispensing with subsequent alcohol- and drug-related problems.</p><p><strong>Methods: </strong>This nationwide register-based study included demographically matched and co-twin control cohorts. Among all Swedish residents aged older than 10 years and BZDR-naïve by 2007, 960,430 BZDR-recipients with incident dispensation in 2007-2019 and without any recorded pre-existing substance-related conditions were identified and matched (1:1) to non-recipients from the general population. Twin BZDR-recipients (<i>n</i> = 12,048) were linked to 12,579 unexposed co-twins. Outcomes included alcohol and drug use disorders, poisoning, deaths, and related suspected criminal offences. Flexible parametric survival models estimated outcome risks across up to 14 years of follow-up.</p><p><strong>Results: </strong>In the demographically matched cohort (60% women, median age at BZDR initiation 51 years), incidence rates in BZDR-recipients and non-recipients (per 1000 person-years) were 5.60 versus 2.79 for alcohol-related and 4.15 versus 1.23 for drug-related problems, respectively. In fully adjusted models, relative risks were increased for alcohol- and drug-related problems (adjusted hazard ratio (95% confidence interval): 1.56 (1.53-1.59) and 2.11 (2.05-2.17), respectively). The risks persisted within the co-twin comparison, different follow-ups, and all additional sensitivity analyses.</p><p><strong>Conclusions: </strong>BZDR initiation was associated with a small but robust increase in absolute and relative risks of developing alcohol- and drug-related problems. The findings contribute to evidence base for making decisions on BZDR treatment initiation.</p>","PeriodicalId":16892,"journal":{"name":"Journal of Psychopharmacology","volume":" ","pages":"2698811251373069"},"PeriodicalIF":5.5,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145206667","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Hypnotics and Suicide: A Tangled Web.","authors":"Andrew S Tubbs, Michael A Grandner, Fabian-Xosé Fernandez","doi":"10.1177/02698811251378129","DOIUrl":"https://doi.org/10.1177/02698811251378129","url":null,"abstract":"","PeriodicalId":16892,"journal":{"name":"Journal of Psychopharmacology","volume":" ","pages":"2698811251378129"},"PeriodicalIF":5.5,"publicationDate":"2025-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145191817","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Escitalopram and functional connectivity in major depressive disorder: A systematic review.","authors":"Fabrizio Turiaco, Federico Arnone, Antonio Drago, Maria Rosaria Anna Muscatello, Antonio Bruno, Fiammetta Iannuzzo","doi":"10.1177/02698811251370998","DOIUrl":"https://doi.org/10.1177/02698811251370998","url":null,"abstract":"<p><p>Functional connectivity (FC) plays a critical role in understanding major depressive disorder (MDD) and treatment mechanisms. Altered FC patterns, particularly within the default mode network (DMN), have been associated with MDD symptoms and therapeutic outcomes. This study systematically reviews the literature on Escitalopram, a selective serotonin reuptake inhibitor (SSRI) with a particular receptor profile, in relation to FC in MDD. A systematic review was conducted using three databases: PubMed, Scopus, and Web of Science. Eleven articles meeting the inclusion criteria were categorized into two groups: treatment effects (six studies) and treatment response prediction (five studies). The six treatment effect studies included 198 patients with MDD and 219 control participants: 205 healthy controls and 14 placebo-treated patients. These studies highlighted Escitalopram's ability to normalize baseline FC disruptions (hypo- or hyperconnectivity), particularly in DMN subsystems. The five treatment prediction studies examined 159 MDD patients, 97 healthy controls, 22 placebo-treated individuals, and 56 non-responders. Poor treatment efficacy was linked to baseline hypoconnectivity in the dorsolateral prefrontal cortex and altered connectivity between the DMN and the frontoparietal network. Overall, Escitalopram treatment appears to restore FC by normalizing both hyperconnectivity and hypoconnectivity patterns associated with MDD, suggesting a rebalancing of network dynamics underlying symptom improvement. Normalization of altered FC patterns after treatment and associations between baseline FC and treatment response suggest FC's potential as a biomarker for understanding and predicting SSRI efficacy.</p>","PeriodicalId":16892,"journal":{"name":"Journal of Psychopharmacology","volume":" ","pages":"2698811251370998"},"PeriodicalIF":5.5,"publicationDate":"2025-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145191814","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Deaths following illicit ketamine use in England, Wales and Northern Ireland 1999-2024: An update report to inform the reclassification debate.","authors":"Jade Pullen, John M Corkery, Rebecca McKnight, Caroline S Copeland","doi":"10.1177/02698811251373058","DOIUrl":"https://doi.org/10.1177/02698811251373058","url":null,"abstract":"<p><strong>Background: </strong>Ketamine is increasingly used in the United Kingdom in non-clinical settings for its psychoactive effects, with rising reports of harms including hospital admissions, dependence and deaths. In light of current debates surrounding the reclassification of ketamine under the Misuse of Drugs Act 1971, up-to-date surveillance of associated mortality is warranted.</p><p><strong>Aims: </strong>We aimed to quantify trends in deaths following illicit ketamine use in England, Wales and Northern Ireland, and to examine changes in demographic and contextual characteristics since the last national analysis which comprised illicit ketamine deaths up to 2019.</p><p><strong>Methods: </strong>Cases where illicit ketamine was detected at post-mortem were extracted from the National Programme on Substance Use Mortality and analysed.</p><p><strong>Results: </strong>There were 696 deaths identified with illicit ketamine between 1999 and 2024. Annual deaths increased over 10-fold from 2014 (15 deaths) to 2024 (197 projected deaths). Whilst absolute deaths implicating illicit ketamine rose (2014: 6 deaths; 2023: 123 projected deaths), the proportion of deaths where illicit ketamine was implicated in causing death declined (2014: 60.0% of cases; 2024: 42.6% of cases). Concurrently, polydrug use increased (median number of co-administered substances 1999-2004: 3; 2005-2009: 3, 2010-2014: 4, 2015-2019: 6; 2020-2024: 6), and the demographic profile of decedents shifted towards greater deprivation and dependence-related contexts.</p><p><strong>Discussion and conclusions: </strong>There has been an acceleration in deaths following illicit ketamine in recent years, which are increasingly featuring complex patterns of polydrug use and socio-economic vulnerability. Policy responses must extend beyond single-substance legislative controls to encompass harm reduction, treatment integration, and social support strategies.</p>","PeriodicalId":16892,"journal":{"name":"Journal of Psychopharmacology","volume":" ","pages":"2698811251373058"},"PeriodicalIF":5.5,"publicationDate":"2025-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145191865","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The effects of antenatal depression and SSRI exposure on children: A systematic review.","authors":"Rubina Fray Gogolu, Alexander Tobias Ysbæk-Nielsen, Jon Lansner","doi":"10.1177/02698811251370973","DOIUrl":"https://doi.org/10.1177/02698811251370973","url":null,"abstract":"<p><strong>Introduction: </strong>Antenatal depression (AD) affects 7%-13% of pregnant women, with adverse implications for mother and child. Treatment often requires pharmacological intervention, typically with selective serotonin reuptake inhibitors (SSRIs). However, it remains unclear whether SSRIs introduce developmental consequences in children distinct from those associated with AD alone. This systematic review aims to elucidate the behavioral and neurological consequences of AD and prenatal SSRI exposure on child development.</p><p><strong>Methods: </strong>A systematic review of databases PubMed, PsycInfo, Web of Science, and Scopus was conducted using the PICO framework. Studies were eligible if they included at least two comparison groups: children with exposure to only AD (AD-only) and those exposed to both AD and in utero SSRIs (AD + SSRI). A total of 14 articles were included.</p><p><strong>Results: </strong>Studies report effects of both AD + SSRI and AD-only exposure on several measures. When compared to controls (CON), both AD + SSRI and AD-only displayed alterations in the corticolimbic system, abnormal language development, and increases in internalizing and externalizing problems. Specific to AD + SSRI were alterations in the corticothalamic system and impairment of psychomotor functioning. Specific to AD-only were steeper white matter volume increases across childhood and lower arousal scores as infants. No significant differences between AD + SSRI, AD-only, and CON were reported on attention and interference suppression. Notably, inconsistencies were found on several measurements, for example, IQ, cortical, and subcortical volume.</p><p><strong>Conclusion: </strong>We present an updated review of the potential implications of AD and SSRIs on child development. Ultimately, a preponderance of observational studies and numerous confounding factors make their effects difficult to disentangle, underscoring the need for further research.</p>","PeriodicalId":16892,"journal":{"name":"Journal of Psychopharmacology","volume":" ","pages":"2698811251370973"},"PeriodicalIF":5.5,"publicationDate":"2025-09-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145137800","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Eight-week antidepressant treatment effects on connectome gradient in first-episode drug-naïve patients with major depressive disorder.","authors":"You-Ran Dai, Yan-Kun Wu, Lin-Lin Zhu, Qian Yu, Ke Li, Ya-Wei Zeng, Ji-Tao Li, Yun-Ai Su, Ming-Rui Xia, Tian-Mei Si","doi":"10.1177/02698811251370981","DOIUrl":"https://doi.org/10.1177/02698811251370981","url":null,"abstract":"<p><strong>Background: </strong>Given the limited understanding of the pathogenesis underlying depression and the specific targets of antidepressant medications, treatment of depression predominantly relies on empirical methodologies. Previous magnetic resonance imaging studies utilizing connectome gradient methods have revealed disruptions of the principal gradient in major depressive disorder (MDD) patients. However, the semiological meaning of the brain gradient and the effect of antidepressants are unknown.</p><p><strong>Methods: </strong>We recruited MDD patients and healthy controls to investigate baseline alterations in the principal connectome gradient. Changes in gradient scores were further analyzed within the responder group post-treatment, and repeated measures ANOVA was used to assess the gradient score changes across time (within-subject) and antidepressant types (between-subject).</p><p><strong>Results: </strong>Compared to controls, MDD patients exhibited gradient score alterations in default and visual networks. After antidepressant treatment, the gradient scores for the left ventromedial prefrontal cortex (VMPFC) increased in patients who responded to therapy. The gradient scores for left VMPFC had an interaction effect between time and antidepressant types and correlated negatively with the core factor scores of HRSD₁₇ at baseline.</p><p><strong>Conclusion: </strong>These results highlight the single-target antidepressants' effects on gradient scores for left VMPFC and provide evidence for future treatment targets and neurobiological underpinnings of antidepressant therapy.</p>","PeriodicalId":16892,"journal":{"name":"Journal of Psychopharmacology","volume":" ","pages":"2698811251370981"},"PeriodicalIF":5.5,"publicationDate":"2025-09-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145131236","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"High dose of psilocybin induces acute behavioral changes without inducing conditioned place preference in Sprague-Dawley rats.","authors":"Vitor Bruno, Martha López-Canul, Brandon Richardson, Rosana Camarini, Tania Marcourakis, Gabriella Gobbi","doi":"10.1177/02698811251368361","DOIUrl":"https://doi.org/10.1177/02698811251368361","url":null,"abstract":"<p><strong>Background: </strong>In recent years, there has been a resurgence of scientific interest in psychedelics, including psilocybin, for their potential in treating neuropsychiatric disorders. However, the reward-related effects of psilocybin and its impact on behavior remain underexplored.</p><p><strong>Aims: </strong>We aimed to evaluate the potential rewarding effects of high doses of psilocybin and its effects on rat behavior.</p><p><strong>Methods: </strong>Sprague-Dawley rats were exposed to the conditioned place preference (CPP) paradigm. Over an 8-day period, rats were administered either psilocybin (10 mg/kg, i.p.) or vehicle (0.9% saline, i.p.) on odd conditioning days, while receiving vehicle (0.9% saline, i.p.) on even conditioning days. The potential rewarding effect induced by psilocybin was assessed 48 hours after the last psilocybin injection. Behavioral assessments, including head twitch, body shaking, grooming, body licking, defecation pellets, and rearing, were conducted during the CPP exposure.</p><p><strong>Results: </strong>Psilocybin did not induce CPP in rats, highlighting its lack of reinforcing effects under these conditions. However, this regimen of administration led to modifications in the behavioral profile during CPP test by increasing head twitching, wet-wet-dog shaking, and defecation pellets and decreasing grooming, body licking, and rearing compared to the vehicle group. Importantly, 48 hours after the final psilocybin injection, no behavioral differences were observed between psilocybin and vehicle groups.</p><p><strong>Conclusion: </strong>Psilocybin at this regimen (10 mg/kg, every other day) does not induce CPP, but induces changes in behavior, which disappear 48 hours after the last injection. More research is needed to better evaluate the addiction liability of psychedelics using different paradigms, doses, and protocols.</p>","PeriodicalId":16892,"journal":{"name":"Journal of Psychopharmacology","volume":" ","pages":"2698811251368361"},"PeriodicalIF":5.5,"publicationDate":"2025-09-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145125035","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}